Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5816530 | Phytomedicine | 2014 | 8 Pages |
Abstract
Results suggest that the primary effect of (+)-PA is inhibition of FASN activity. Synergistic effects with lapatinib were seen only in SK-BR-3 cells, and not T-47D cells, further supporting the notion that (+)-PA acts by inhibiting FASN with secondary effects on HER2 expression and signalling. (+)-PA could therefore be a suitable agent for further testing, alone or in combination treatment against HER2-overexpressing breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Margrét Bessadóttir, Edda Á. Skúladóttir, Sharon Gowan, Suzanne Eccles, Sesselja Ãmarsdóttir, Helga M. Ãgmundsdóttir,